Overexpression of proteasome 26S subunit non-ATPase 6 protein and its clinicopathological significance in intrahepatic cholangiocarcinoma

BACKGROUND Currently,intrahepatic cholangiocarcinoma(ICC)poses a continuing,significant health challenge,but the relationship has yet to be established between ICC and the proteasome 26S subunit non-ATPase 6(PSMD6).AIM To investigate the protein expression and clinicopathological significance of PSMD6 in ICC.METHODS The potential impact of the PSMD6 gene on the growth of ICC cell lines was analyzed using clustered regularly interspaced short palindromic repeat knockout screening technology.Forty-two paired specimens of ICC and adjacent noncancerous tissues were collected.PSMD6 protein expression was determined by immunohistochemistry.Receiver operating characteristic curve analysis was performed to validate PSMD6 expression level,and its association with ICC patients’various clinicopathological characteristics was investigated.RESULTS The PSMD6 gene was found to be essential for the growth of ICC cell lines.PSMD6 protein was significantly overexpressed in ICC tissues(P<0.001),but showed no significant association with patient age,gender,pathological grade,or tumor-node-metastasis stage(P>0.05).CONCLUSION PSMD6 can promote the growth of ICC cells,thus playing a pro-oncogenic role.

Is 26S proteasome non-ATPase regulatory subunit 6 a potential molecular target for intrahepatic cholangiocarcinoma?

In this editorial we comment on the article by Tang et al published in the recent issue of World Journal of Hepatology.Drug therapy of intrahepatic cholangiocarcinoma(iCCA)poses an enormous challenge since only a small proportion of patients demonstrate beneficial responses to therapeutic agents.Thus,there has been a sustained search for novel molecular targets for iCCA.The study by Tang et al evaluated the role of 26S proteasome non-ATPase regulatory subunit 6(PSMD6),a 19S regulatory subunit of the proteasome,in human iCCA cells and specimens.The authors employed clustered regularly interspaced short palindromic repeat(CRISPR)knockout screening technology integrated with the computational CERES algorithm,and analyzed the human protein atlas(THPA)database and tissue microarrays.The results show that PSMD6 is a gene essential for the proliferation of 17 iCCA cell lines,and PSMD6 protein was overexpressed in iCCA tissues without a significant correlation with the clinicopathological parameters.The authors conclude that PSMD6 may play a promoting role in iCCA.The major limitations and defects of this study are the lack of detailed information of CRISPR knockout screening,in vivo experiments,and a discussion of plausible mechanistic cues,which,therefore,dampen the significance of the results.Further studies are required to verify PSMD6 as a molecular target for developing novel therapeutics for iCCA.In addition,the editorial article summarizes the latest advances in molecular targeted drugs and recently emerging immunotherapy in the clinical management of iCCA,development of proteasome inhibitors for cancer therapy,and advantages of CRISPR screening technology,computational methods,and THPA database as experimental tools for fighting cancer.We hope that these comments may provide some clues for those engaged in the field of basic and clinical research into iCCA.

整合素α6靶向自组装促凋亡纳米多肽对中枢神经系统急性淋巴细胞白血病的靶向治疗

There is currently no effective targeted therapeutic strategy for the treatment of central nervous system acute lymphoblastic leukemia(CNS-ALL).Integrinα6 is considered a potential target for CNS-ALL diagnosis and therapy because of its role in promoting CNS-ALL disease progression.The targeted peptide D(RWYD)(abbreviated RD),with nanomolar affinity to integrinα6 was identified by peptide scanning techniques such as alanine scanning,truncation,and D-substitution.Herein,we developed a therapeutic nanoparticle based on the integrinα6-targeted peptide for treating CNS-ALL.The self-assembled proapoptotic nanopeptide_(D)(RWYD)-_(D)(KLAKLAK)_(2)-G_(D)(FFY)(abbreviated RD-KLA-Gffy)contains the integrinα6-targeted peptide RD,the well-known proapoptotic peptide_(D)(KLAKLAK)_(2)(abbreviated KLA),and the self-assembling tetrapeptide GD(FFY)(abbreviated Gffy).The functional mechanism of RD-KLA-Gffy is clarified using different experiments.Our results demonstrate that RD-KLA-Gffy is highly enriched in CNS-ALL lesions and induces tumor cell apoptosis,thus reducing CNS-ALL disease burden and prolonging the survival of CNS-ALL mice without obvious toxicity.Moreover,the combined use of RD-KLA-Gffy and methotrexate(MTX)shows a potent antitumor effect in treating CNS-ALL,indicating that RD-KLA-Gffy plays an important role in suppressing CNS-ALL progression either as a single agent or in combination with MTX,which shows promise for application in CNS-ALL therapy.

Unveiling the therapeutic potential:KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation in vitro

Background:Triple-negative breast cancer(TNBC)is a heterogeneous,recurring cancer characterized by a high rate of metastasis,poor prognosis,and lack of efficient therapies.KBU2046,a small molecule inhibitor,can inhibit cell motility in malignant tumors,including breast cancer.However,the specific targets and the corresponding mechanism of its function remain unclear.Methods:In this study,we employed(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium)(MTS)assay and transwell assay to investigate the impact of KBU2046 on the proliferation and migration of TNBC cells in vitro.RNA-Seq was used to explore the targets of KBU2046 that inhibit the motility of TNBC.Finally,confirmed the predicted important signaling pathways through RT-qPCR and western blotting.Results:In this study,we found that KBU2046 functioned as a novel transforming growth factor-β(TGF-β1)inhibitor,effectively suppressing tumor cell motility in vitro.Mechanistically,it directly down-regulated leucine-rich repeat-containing 8 family,member E(LRRC8E),latent TGFβ-binding protein 3(LTBP3),dynein light chain 1(DNAL1),and MAF family of bZIP transcription factors(MAFF)genes,along with reduced protein expression of the integrin family.Additionally,KBU2046 decreased phosphorylation levels of Raf and ERK.This deactivation of the ERK signaling pathway impeded cancer invasion and metastasis.Conclusions:In summary,these findings advocate for the utilization of TGF-β1 as a diagnostic and prognostic biomarker and as a therapeutic target in TNBC.Furthermore,our data underscore the potential of KBU2046 as a novel therapeutic strategy for combating cancer metastasis.

CD44v6、MMP_2和β_1integrins在CINⅡ-Ⅲ、宫颈鳞形细胞癌中的表达和意义

目的通过研究CD44v6、MMP2和β1integrins在CINⅡ-Ⅲ、宫颈鳞形细胞癌组织中的表达,探讨细胞外基质降解在宫颈鳞形细胞癌发生发展中的作用。方法收集宫颈鳞形细胞癌组织切片20例,CINⅡ-Ⅲ组织切片15例,正常宫颈组织切片10例,免疫组化法检测CD44v6、MMP2和β1integrins表达。结果CD44v6低表达与CINⅡ-Ⅲ病变有相关性(P<0.05),与宫颈鳞形上皮癌变有高度相关性(P<0.001);β1integrins低表达与CINⅡ-Ⅲ病变有高度相关性(P<0.001);MMP2高表达与宫颈鳞形上皮癌变有高度相关性(P<0.001),但与CINⅡ-Ⅲ病变无相关性(P>0.05)。结论CD44v6、β1integrins和MMP2的异常表达与宫颈鳞癌的发生发展有关,细胞外基质作用减弱有利于宫颈癌变的发生,其本身结构的破坏有利于宫颈癌的浸润。

人源蛋白酶体α亚基6(Proteasome subunit alpha 6)在酿酒酵母表面展示

为构建人源蛋白酶体α亚基6(α6)的酵母展示体系,研制其单克隆抗体用于抗体表位分析和研究泛素-蛋白酶体途径,建立绕过重组抗原表达及纯化制备、将展示重组抗原直接应用于抗体检测的方法.在酵母展示表达载体pICAS中引入His.tag标签,将编码α6的基因PSA6_HUMAN克隆到酵母表面展示载体pICAS-H上,用流式细胞仪检测其抗原表位活性,以表面展示α6的重组酵母细胞,结合酶联吸附免疫检测技术,建立酵母(yeast)-ELISA检测技术,应用于检测小鼠单克隆抗体及单抗效价.酵母细胞培养48h后获得抗原α6的高效表面展示,展示的α6具有良好的抗原活性和特异性,将α6的展示酵母用于yeast-ELISA的初步实验结果显示可有效检测和筛选到抗α6抗体.

Integrin α_5β_1及CD_(44V6)在卵巢上皮性肿瘤的表达及临床意义

目的:通过研究integrinα5β1及CD44V6在卵巢上皮性肿瘤中的表达,探讨各指标与卵巢癌淋巴结转移的关系。方法:用免疫组化ElivisionTM法检测80例卵巢上皮性肿瘤中integrinα5β1及CD44V6的表达。结果:integrinα5β1的表达按良性、交界性及恶性的顺序呈递减趋势,组间均有显著性差异(P<0.01);CD44V6的表达则呈递增趋势,组间有显著性差异(P<0.05);integrinα5β1淋巴结转移组与未转移组间表达有显著性差异(P<0.05);integrinα5β1与CD44V6的表达呈负相关。结论:integrinα5β1表达下降或缺失,CD44V6表达升高,提示肿瘤进展,恶性度高,预后不良;计算机图像分析系统对卵巢上皮性肿瘤的自动化诊断、淋巴结转移及预后评估有重要意义。

Integrinβ1和CD_(44)V_6在子宫内膜癌组织中的表达及与癌生物学行为的关系

目的探讨Integrinβ1和CD44V6在子宫内膜癌中的表达及与癌生物学行为之间的关系。方法采用免疫组织化学染色法检测84例子宫内膜癌、20例非典型子宫内膜增生和14例增殖期子宫内膜Integrinβ1和CD44V6的表达情况。结果子宫内膜癌组织中Integrinβ1和CD44V6的表达阳性率明显高于非典型子宫内膜增生(P均<0.05)和增殖期子宫内膜(P<0.01或0.05);Integrinβ1的表达与子宫浆膜侵犯(u=3.07,P<0.01),病理分级(u=3.77,P<0.01)及肿瘤转移(u=3.66,P<0.01)关系密切;CD44V6在有肿瘤转移组织中的阳性表达率显著高于无肿瘤转移的组织(χ2=5.12,P<0.05)。结论Integrinβ1和CD44V6在子宫内膜癌中的明显表达可能与其浸润转移的生物学行为有关。

粘附分子CD44V6及Integrinαvβ_3在胆囊癌中的表达及意义

目的研究粘附分子CD44V6及Integrinαvβ_3在胆囊癌组织及胆囊炎中表达是否存在统计学意义的差异,其表达量与胆囊癌的分化程度之间的关系。方法应用免疫组织化学的方法检测20例胆囊癌及20例慢性胆囊炎组织中CD44V6及Integrinαvβ_3的表达,结合临床病理结果进行分析。结果在胆囊癌中CD44V6和Integrinαvβ_3表达阳性率分别为80.0%和70.0%。CD44V6及Integrinαvβ_3在胆囊癌中表达存在协同性,与胆囊癌分化程度呈正相关(均P<0.05)。结论 CD44V6及Integrinαvβ_3在胆囊癌中高表达(显著高于对照组),并且随着胆囊癌的分化程度降低其表达阳性分值增高;CD44V6及Integrinαvβ_3的表达与原发性胆囊癌的良恶性及分化程度相关;在相同标本中,CD44V6高表达往往伴有Integrinαvβ_3高表达,在胆囊癌的诊断上具有一致性,可联合作为临床监测胆囊癌发生、转移的参考指标。

integrin α6和MKK4基因在卵巢癌不同淋巴结转移能力细胞系中的表达及其意义

目的:探讨integrin α6、MKK4基因在卵巢癌不同淋巴结转移能力细胞亚系的表达及其意义。方法:采用TRIZOL一步法抽提卵巢癌不同淋巴结转移能力细胞的总RNA,逆转录合成CDNA,应用RT-PCR技术检测integrin α6、MKK4基因在不同细胞亚系表达的灰度值,应用实时荧光定量PCR技术对integrin α6、MKK4基因在不同细胞亚系的表达进行定量分析。结果:integrin α6基因在SKOV3、SKOV3-PM2、SKOV3-PM3细胞系中的表达呈上升趋势,但在SKOV3-PM4细胞系中的表达低于SKOV3细胞系。MKK4基因表达量在SKOV3、SKOV3-PM2、SKOV3-PM3、SKOV3-PM4细胞系呈逐渐下降趋势。结论:integrin α6表达上调和MKK4表达下调与卵巢癌的淋巴结定向高转移过程密切相关,出现integrin α6在SKOV3-PM4细胞系表达的下调的现象,可能存在整合素各亚单位之间的相互调控。

Integrinβ1和CD44v6蛋白在皮肤黑素瘤中的表达

目的探讨Integrinβ1和CD44v6在皮肤黑素瘤组织中的表达及意义。方法采用免疫组化ABC法检测Integrinβ1和CD44v6蛋白在36例皮肤黑素瘤、34例色素痣及31例正常皮肤组织中的表达。结果Integrinβ1在正常对照、色素痣和黑素瘤组织中表达的阳性率分别为41.9%,47.1%和77.7%,在黑素瘤组织中的表达强度显著高于色素痣和正常对照(P<0.05);CD44v6在正常对照、色素痣和黑素瘤组织中的阳性率分别为51.6%,58.8%和75.0%,三组间表达无显著差异(P>0.05)。Integrinβ1和CD44v6在黑素瘤IV～V级组和有淋巴结转移组中的表达强度显著高于I～III级组和无淋巴结转移组(P<0.05);二者在黑素瘤组织中表达呈正相关(r=0.463,P<0.05)。结论Integrinβ1和CD44v6的表达与皮肤黑素瘤的发生发展及浸润转移有关。

Integrin αvβ6 and matrix metalloproteinase 9 correlate with survival in gastric cancer

AIM: To investigate the expression of integrin αvβ6 and matrix metalloproteinase 9 (MMP-9), their association with prognostic factors and to assess their predictive role in gastric cancer patients.METHODS: Immunohistochemistry was used to determine the expressions of integrin αvβ6 and MMP-9 in 126 specimens from patients with primary gastric carcinoma. Associations between immunohistochemical staining and various clinic pathologic variables of tissue specimens were evaluated by the χ2 test and Fisher’s exact test. Expression correlation of αvβ6 and MMP-9 was assessed using bivariate correlation analysis. The patients were followed-up every 3 mo in the first two years and at least every 6 mo afterwards, with a median follow-up of 56 mo (ranging from 2 mo to 94 mo). Four different combinations of αvβ6 and MMP-9 levels (that is, both markers positive, both markers negative, αvβ6 positive with MMP-9 negative, and αvβ6 negative with MMP-9 positive) were evaluated for their relative effect on survival. The difference in survival curves was evaluated with a log-rank test. Survival analysis was conducted using the Kaplan-Meier survival and Cox proportional hazards model analysis.RESULTS: The expressions of integrin αvβ6 and MMP-9 were investigated in 126 cases, among which 34.92% were positive for αvβ6 expression, and 42.06% for MMP-9 expression. The expression of αvβ6 was associated with Lauren type, differentiation, N stage, and TNM stage (the P values were 0.006, 0.038, 0.016, and 0.002, respectively). While MMP-9 expression was associated with differentiation, T stage, N stage, and TNM stage (the P values were 0.039, 0.014, 0.033, and 0.008, respectively). The positive correlation between αvβ6 and MMP-9 in gastric cancer was confirmed by a correlation analysis. The Kaplan-Meier survival analysis showed that patients with expression of αvβ6 or MMP-9 alone died earlier than those with negative expression and that patients who were both αvβ6 and MMP-9 positive had a shorter overall survival than those with the opposite pattern (both αvβ6 and MMP-9 negative) (P = 0.000). A Cox model indicated that positive expression of αvβ6 and MMP-9, diffuse Lauren type, as well as a senior grade of N stage, M stage, and TNM stage were predictors of a poor prognosis in univariate analysis. Only αvβ6 and MMP-9 retained their significance when adjustments were made for other known prognostic factors in multivariate analysis (RR = 2.632, P = 0.003 and RR = 1.813, P = 0.007).CONCLUSION: The expression of αvβ6 and MMP-9 are closely correlated, and the combinational pattern of αvβ6 and MMP-9 can serve as a more effective prognostic index for gastric cancer patients.

Integrin αvβ6 sustains and promotes tumor invasive growth in colon cancer progression

AIM: To detect the mechanism by which colon tumor escapes the growth constraints imposed on normal cells by cell crowding and dense pericellular matrices.METHODS: An immunohistochemical study of integrin αvβ6 and matrix metalloproteinase-9(MMP-9) was performed on tissue microarrays of 200 spots, including 100 cases of colon tumors. RESULTS: High immunoreactivity for αvβ6(73.7%; 28/38) and MMP-9(76.5%; 52/68) was observed in invasive tumor portions. Furthermore, the effects of integrin αvβ6 on tumor invasive growth in nude mice were detected. Tumor invasive growth and high expression of both αvβ6 and MMP-9 were only seen in tumors resulting from Wi Dr cells expressing αvβ6 in the tumorigenicity assay. Flow cytometry was applied to analyze αvβ6 expression in colon cancer Wi Dr and SW480 cells. The effects of cell density on αvβ6 expression and MMP-9 secretion were also detected by Biotrak MMP-9 activity assay and gelatin zymography assay. High cell density evidently enhanced αvβ6 expression and promoted MMP-9 secretion compared with low density. CONCLUSION: Integrin αvβ6 sustains and promotes tumor invasive growth in tumor progression via a selfperpetuating mechanism. Integrin ανβ6-mediated MMP-9 secretion facilitates pericellular matrix degradation at high cell density, which provides the basis of invasive growth.

Influence of Cell Confluency on the Expression of the α4 Integrin Subunit of Retinal Pigment Epithelial Cells

Integrins are a family of transmembrane glycoproteins that mediate cell-cell and cell-extracellular matrix interactions. The integrin α4 subunit is widely expressed by cells from the immune system and its expression by non-hematopoietic cells is scarce. In the present study, gene and protein expression of this integrin subunit was characterized in proliferating and quiescent human RPE cells. Immunofluorescent studies confirm that the α4 subunit is expressed in vitro by RPE cells, a result that has been validated by immunofluorescence and FACS analyses. The accumulation of the α4 integrin at cell-cell junctions in post-confluent RPE cell cultures negatively correlated with the level of expression of the mRNA transcript. Accordingly, transient transfection analyses reveal that the α4 promoter activity is considerably reduced when RPE cells form a confluent monolayer. Moreover, transfection of recombinant constructs bearing 5’-deletions of the α4 promoter segment allows the localization of strong negative regulatory elements on the -76 to -300 region of the α4 gene suggesting that its expression is intimately linked to the proliferative state of primary cultured RPE cells.

Identification of integrin β6 gene promoter and analysis of its transcription regulation in colon cancer cells

BACKGROUND The integrinβ6 gene,which is expressed in epithelial cancer,plays a pivotal role in various aspects of cancer progression.The present research for integrinβ6 regulation mainly focuses on the post-transcription and translation related regulation mechanism and its role in tumorigenesis.The mechanisms of how the integrinβ6 gene is regulated transcriptionally,and the promoter and transcription factors responsible for basic transcription of integrinβ6 gene remain unknown.AIM To clone and characterize the integrinβ6 promoter.METHODS Software analysis was used to predict the region of integrinβ6 promoter.Luciferase reporter plasmids,which contained the integrinβ6 promoter,were constructed.Element deletion analysis was performed to identify the location of core promoter and binding sites for transcription factors.RESULTS The regulatory elements for the transcription of the integrinβ6 gene were located between-286 and-85 and contained binding sites for transcription factors such as STAT3 and Ets-1.CONCLUSION For the first time,we found the region ofβ6 core promoter and demonstrated the binding sites for transcription factors such as Ets-1 and STAT3,which are important for integrinβ6 promoter transcription activity.These findings are important for investigating the mechanism of integrinβ6 activation in cancer progression.

CopE and TLR6 RNAi-mediated tomato resistance to western flower thrips

The western flower thrips(WFT;Frankliniella occidentalis)is a mesophyll cell feeder that damages many crops.Management of WFT is complex due to factors such as high fecundity,short reproduction time,ability to feed on a broad range of host plants,and broad pesticide resistance.These challenges have driven research into developing alternative pest control approaches for WFT.This study analyzed the feasibility of a biological control-based strategy to manage WFT using RNA interference(RNAi)-mediated silencing of WFT endogenous genes.For the delivery of RNAi,we developed transgenic tomato lines expressing double-stranded RNA(dsRNA)of coatomer protein subunit epsilon(CopE)and Toll-like receptor 6(TLR6)from WFT.These genes are involved in critical biological processes of WFT,and their dsRNA can be lethal to these insects when ingested orally.Adult WFT that fed on the transgenic dsRNAexpressing tomato flower stalk showed increased mortality compared with insects that fed on wild-type samples.In addition,WFT that fed on TLR6 and CopE transgenic tomato RNAi lines showed reduced levels of endogenous CopE and TLR6 transcripts,suggesting that their mortality was likely due to RNAi-mediated silencing of these genes.Thus,our findings demonstrate that transgenic tomato plants expressing dsRNA of TLR6 and CopE can be lethal to F.occidentalis,suggesting that these genes may be deployed to control insecticide-resistant WFT.

RNA-binding protein CPSF6 regulates IBSP to affect pyroptosis in gastric cancer

BACKGROUND Extensive evidence has illustrated the promotive role of integrin binding sialoprotein(IBSP)in the progression of multiple cancers.However,little is known about the functions of IBSP in gastric cancer(GC)progression.AIM To investigate the mechanism underlying the regulatory effects of IBSP in GC progression,and the relationship between IBSP and cleavage and polyadenylation factor 6(CPSF6)in this process.METHODS The mRNA and protein expression of relevant genes were assessed through realtime quantitative polymerase chain reaction and Western blot,respectively.Cell viability was evaluated by Cell Counting Kit-8 assay.Cell invasion and migration were evaluated by Transwell assay.Pyroptosis was measured by flow cytometry.The binding between CPSF6 and IBSP was confirmed by luciferase reporter and RNA immunoprecipitation(RIP)assays.RESULTS IBSP exhibited higher expression in GC tissues and cell lines than in normal tissues and cell lines.IBSP knockdown suppressed cell proliferation,migration,and invasion but facilitated pyroptosis.In the exploration of the regulatory mechanism of IBSP,potential RNA binding proteins for IBSP were screened with catRAPID omics v2.0.The RNA-binding protein CPSF6 was selected due to its higher expression in stomach adenocarcinoma.Luciferase reporter and RIP assays revealed that CPSF6 binds to the 3’-untranslated region of IBSP and regulates its expression.Knockdown of CPSF6 inhibited cell proliferation,migration,and invasion but boosted pyroptosis.Through rescue assays,it was uncovered that the retarded GC progression mediated by CPSF6 knockdown was reversed by IBSP overexpression.CONCLUSION Our study highlighted the vital role of the CPSF6/IBSP axis in GC,suggesting that IBSP might be an effective biotarget for GC treatment.

膀胱癌组织中脂肪酸结合蛋白6、核苷酸还原酶M1亚基的表达及与临床病理特征的相关性

目的:探究膀胱癌(bladder cancer)组织中脂肪酸结合蛋白6(fatty acid-binding protein6,FABP6)、核苷酸还原酶M1亚基(ribonucleotide reductase regulatory subunit M1,RRM1)的表达水平及其与膀胱癌患者临床病理特征的相关性。方法:回顾性分析2020年2月-2021年12月大冶市人民医院收治的并接受手术切除的40例膀胱癌患者的临床资料。采用免疫组化法检测各组织中的FABP6和RRM1蛋白表达水平,并分析FABP6和RRM1蛋白与各项临床特征的关系。结果:膀胱癌组织中FABP6和RRM1高蛋白表达水平占比均高于癌旁正常组织(P<0.05)。FABP6和RRM1蛋白高表达和低表达膀胱癌患者的性别、年龄、肿瘤类型、肿瘤直径比较,差异均无统计学意义(P>0.05)。FABP6和RRM1蛋白高表达和低表达膀胱癌患者的分化程度、TNM分期、淋巴结转移比较,差异均有统计学意义(P<0.05)。结论:FABP6、RRM1在膀胱癌组织中表达水平高于癌旁正常组织,且两者均参与了膀胱癌的发生、发展进程。

口蹄疫病毒受体猪源整联蛋白β6亚基配体结合域多克隆抗体的制备和特性分析

目的:表达口蹄疫病毒受体猪源整联蛋白β6亚基配体结合域β6LBD,并制备兔抗β6LBD多克隆抗体。方法:利用PCR方法扩增整联蛋白β6LBD基因片段,经BamHⅠ和XhoⅠ进行双酶切后连入pGEX-4T-1原核表达载体,构建的pGEX-4T-1-β6LBD重组表达质粒,转化大肠杆菌BL21(DE3)菌株,经IPTG诱导表达,SDS-PAGE鉴定融合蛋白的表达并提取包涵体,纯化目的蛋白。然后用纯化的蛋白免疫新西兰大耳白兔制备其多克隆抗体,以ELISA方法测定抗体效价,并以Western blot鉴定其特异性。结果:SDS-PAGE电泳分析显示pGEX-4T-1-β6LBD诱导后表达一Mr约为42000的GST-β6LBD融合蛋白,与预期结果相符。目的蛋白纯化后,在电泳图片上显示较为清晰的单一条带,用纯化GST-β6LBD免疫新西兰大耳白兔制备的多克隆抗体效价达1∶12800以上,具有较高的特异性。结论:制备了具有高亲和性和特异性的抗猪源整联蛋白β6LBD多克隆抗体,为深入研究整联蛋白β6在口蹄疫病毒感染过程中的作用了奠定基础。

口蹄疫病毒受体猪源整联蛋白β6亚基配体结合域单克隆抗体的制备

以纯化的口蹄疫病毒受体猪源整联蛋白β6亚基配体结合域重组蛋白为抗原,免疫雌性BALB/c小鼠,经3次免疫后取其脾细胞与SP2/0骨髓瘤细胞融合,制备口蹄疫病毒受体猪源整联蛋白β6亚基配体结合域单克隆抗体(McAb);采用有限稀释法和间接ELISA克隆和筛选阳性杂交瘤细胞株,并用SDS-PAGE、间接ELISA以及间接免疫荧光法对制备的McAb的特异性进行鉴定。结果显示,成功获得5株能稳定传代并分泌抗β6亚基配体结合域的杂交瘤细胞株,分别命名为C4C7、E7C7、B8C9、C2D8和B7B6,其分泌的McAb为IgG2b(C2D8)和IgG2a(C4C7、E7C7、B8C9、B7B6)亚类。制备的口蹄疫病毒受体猪源整联蛋白β6亚基配体结合域McAb可为深入研究整联蛋白αvβ6在口蹄疫病毒感染过程中的作用奠定基础。